Doctors Are Using This To Outsmart Cancer!

Dr. Dino Prato introduces circulating tumor cells, or CTCs, a promising biomarker in cancer diagnosis. This method gives oncologists insight into a patient's prognosis and can guide precision medicine for cancer treatment. Learn how CTCs from a simple ctc blood tests can reshape cancer care and help you track cancer progression and treatment response?In this episode, Dr. Dino Prato discusses the science behind Circulating Tumor Cell (CTC) testing—an emerging tool that may provide insight into tumor behavior, treatment response, and disease progression.🔬 What You’ll Learn:What CTCs are and how they enter the bloodstreamWhy CTC levels may correlate with prognosis (per peer-reviewed studies)How CTC data is used alongside genomics, immune profiling, and transcriptomics at Envita Medical CentersLimitations of conventional oncology in adopting new technologies⚠️ CTC testing is not FDA-approved as a standalone diagnostic tool and should not replace conventional imaging or biopsy. It is used as part of a broader integrative care model.Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493